Business
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China). Strategic Priority: Advancing Clinical Development of LBL-047 LBL-047 is
About this update from Nanjing Leads Biolabs Co., Ltd. Class H
[{"type":"text","content":"NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China).","length":440,"tagName":"p"},{"type":"text","content":"Strategic Priority: Advancing Clinical Development of LBL-047","length":61,"tagName":"p"},{"type":"text","content":"LBL-047 is a potential first- and best-in-disease bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes.","length":429,"tagName":"p"},{"type":"text","content":"As a core pipeline asset and strategic priority, Dianthus is advancing the clinical development of LBL-047 in SjD, SLE, and DM — three indications with high unmet medical need. In March 2026, Dianthus completed an upsized underwritten public offering, raising approximately $719 million in gross proceeds, providing a strong capital foundation to support the global development of LBL-047.","length":389,"tagName":"p"},{"type":"text","content":"Phase 1 Data Anticipated in 2H’26","length":33,"tagName":"p"},{"type":"text","content":"A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with SLE (Part B) was initiated in December 2025, with top-line results in healthy volunteers expected in 2H’26. Upon completion of the Phase 1 study, Dianthus plans to provide an update on next steps for advancing its prioritized indications in clinical development.","length":345,"tagName":"p"},{"type":"text","content":"About LBL-047LBL-047 is a bifunctional fusion protein composed of a humanized anti-blood dendritic cell antigen 2 (BDCA2) antibody and an engineered transmembrane activator and CAML interactor (TACI) ectodomain. It is designed to selectively deplete pDCs to reduce type 1 interferon production, while simultaneously inhibiting B-cell activ...